ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in patients with heart failure, even in those without diabetes.

Adding empagliflozin to optimal medical therapy lowers the risk of cardiovascular events in patients with heart failure and reduced ejection fraction. Such events include heart failure hospitalization, worsening kidney failure—even mortality.

Originally approved for glucose control, this sodium–glucose cotransporter 2 (SGLT2) inhibitor lowers event rates even in non-diabetic patients.

The EMPEROR study, presented virtually at the European Society of Cardiology 2020 Congress (ESC 2020) and published simultaneously in the New England Journal of Medicine (NEJM), studied empagliflozin, making it the second randomized trial showing benefits from this drug family. In November 2019, during the American Heart Association (AHA) congress, the DAPA-HF study kickstarted this line of research using dapagliflozin.


Read also: ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy.


EMPEROR included patients with a mean ejection fraction of 27.7% and nearly three-quarters of patients had an ejection fraction of less than 30%. Additionally, the vast majority (roughly 80%) of patients had NT-proBNP levels 1000 pg/mL or higher.

In the study, 3730 patients with heart failure were randomized to treatment with empagliflozin or placebo. Both study groups received optimal medical treatment with inhibitors of the renin-angiotensin system, inhibitors of the neprilysin receptors, beta-blockers, mineralocorticoid receptor antagonists, and cardiac devices, eventually. The trial included a similar number of patients with and without diabetes.

The primary endpoint—a composite of cardiovascular death or hospitalization for worsening heart failure—occurred in 19.4% of patients treated with empagliflozin and 24.7% of those who received placebo (hazard ratio [HR]: 0.75; 95% confidence interval [CI]: 0.65-0.86) over a 16-month follow-up. Additionally, empagliflozin reduced the composite renal endpoint by 50%.

emperor-full

Original Title: Cardiovascular and renal outcomes with empagliflozin in heart failure.

Reference: Packer M et al. N Engl J Med. 2020; Epub ahead of print y presentado en forma virtual en el ESC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....